Phaseline

Targets › ALOX5

ALOX5 (Polyunsaturated fatty acid 5-lipoxygenase): drug programs, companies and trials

7 programs from 7 companies in 7 trials: 5 Phase 2, 2 Phase 1; Oncology, Other, Immunology; next expected readout Dec 2026.

Catalyzes the oxygenation of arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) to 5-hydroperoxyeicosatetraenoate (5-HPETE) followed by the dehydration to 5,6- epoxyeicosatetraenoate (Leukotriene A4/LTA4), the first two steps in the biosynthesis of leukotrienes, which are potent mediators of inflammation. Also catalyzes the oxygenation of arachidonate into 8-hydroperoxyicosatetraenoate (8-HPETE) and…. (UniProt, P09917)

Open in Phaseline: the race on ALOX5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Massachusetts General HospitalOmega 3 (EPA-enriched)
Pro-resolving lipid mediator precursor; substrate for production of specialized pro-resolv
PTGS1, PTGS2, ALOX5Phase 2Treatment Resistant DepressionMar 2027
AHS Cancer Control AlbertaMesalamine
Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor
ALOX5, PPARG, PTGS2, PTGS1Phase 2Immune-related Adverse EventAug 2027
NYU Langone HealthSulfasalazine
Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor
ALOX5, PTGS2, PTGS1Phase 2Rheumatic DiseaseJan 2028
Rutgers, The State University of New JerseySulfasalazine
Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor
ALOX5, PTGS2, PTGS1Phase 2Preterm BirthJan 2028
Ann-Sofie BackmanMesalamine
Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor
ALOX5, PPARG, PTGS2, PTGS1Phase 2Lynch SyndromeSep 2032
University of ZurichSulfasalazine
Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor
ALOX5, PTGS2, PTGS1Phase 1GlioblastomaDec 2026
Assistance Publique - Hôpitaux de ParisSulfasalazine
Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor
ALOX5, PTGS2, PTGS1Phase 1Acute Myeloid LeukemiaDec 2026

Conditions

Glioblastoma (1) Preterm Birth (1) Rheumatic Disease (1) Acute Myeloid Leukemia (1) Treatment Resistant Depression (1) Lynch Syndrome (1) Immune-related Adverse Event (1)

Modalities

small molecule (6), mixed (1)

Companies

University of Zurich (1) Rutgers, The State University of New Jersey (1) NYU Langone Health (1) Assistance Publique - Hôpitaux de Paris (1) Massachusetts General Hospital (1) Ann-Sofie Backman (1) AHS Cancer Control Alberta (1)

Related targets

PTGS2 (7) PTGS1 (7) PPARG (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.